Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Sep 16, 2019 11:19am
230 Views
Post# 30131250

RE:RE:Resverlogix Provides Update on BETonMACE Phase 3 Trial

RE:RE:Resverlogix Provides Update on BETonMACE Phase 3 Trial"very specific.  am i to believe that we have landed the late breaking session at AHA then!? to be announced this week?  that hasn't been announced yet, and over at agora BDaz posted a link to some tweets for last week and early this week, so we're waiting for that? BUT... they have something on the books for CTAD in Dec San Diego? Guess nothing for ASN Kidney week conference Nov 6-10? And nothing for CTAD Asia Oct 11-12? I like the AHA placeholder, and the AD placeholder, where is the placeholder for Renal!?"

Yes, AHA announces late breakers this week. Get your popcorn ready!

My take on this is that Resverlogix want the FIRST data presentation for BETonbMACE to be at AHA (Nov 16-18). CTAD Asia is a smaller CTAD conference compared to the one in December and happens in October (prior to AHA). The schedule was set for CTAD Asia a while ago, so they probably missed the deadline on that one. The large CTAD in San Diego is probably a better venue anyway. The big American Society for Nephrology Kidney Week 2019 meeting is November 5-10, also prior to AHA. So if AHA comes first, then the next renal conference to present full renal data after ASN might not be until 2020. However, it is likely that they would reveal in news release some details (meeting endpoint, p-value, magnitude of change, etc) prior to whatever renal meeting they present at. 

BearDownAZ


Bullboard Posts